Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Melanoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Solid Tumor (16716
)
Ocular Melanoma (110
)
Uveal Melanoma (105
)
Cutaneous Melanoma (90
)
Mucosal Melanoma (33
)
Solid Tumor (16716
)
Ocular Melanoma (110
)
Uveal Melanoma (105
)
Cutaneous Melanoma (90
)
Mucosal Melanoma (33
)
›
Associations
(1044)
News
Trials
VERI cancer hierarchy
Reset Filters
NRAS mutation
Melanoma
NRAS mutation
Melanoma
PDR001 + ERAS-254
Sensitive: C3 – Early Trials
Eur J Cancer - 1 week (New C3)
PDR001 + ERAS-254
Sensitive
:
C3
Eur J Cancer - 1wk
PDR001 + ERAS-254
Sensitive: C3 – Early Trials
Eur J Cancer - 1 week
PDR001 + ERAS-254
Sensitive
:
C3
Eur J Cancer - 1 week - (New C3)
CD52 overexpression
Melanoma
CD52 overexpression
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
Pigment Cell Melanoma Res - 2 weeks (New C3)
Immunotherapy
Sensitive
:
C3
Pigment Cell Melanoma Res - 2wk
Immunotherapy
Sensitive: C3 – Early Trials
Pigment Cell Melanoma Res - 2 weeks
Immunotherapy
Sensitive
:
C3
Pigment Cell Melanoma Res - 2 weeks - (New C3)
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib + dabrafenib + phenformin
Sensitive: C3 – Early Trials
Cancer Res Commun - 3 weeks (New C3)
trametinib + dabrafenib + phenformin
Sensitive
:
C3
Cancer Res Commun - 3wk
trametinib + dabrafenib + phenformin
Sensitive: C3 – Early Trials
Cancer Res Commun - 3 weeks
trametinib + dabrafenib + phenformin
Sensitive
:
C3
Cancer Res Commun - 3 weeks - (New C3)
IFNG gene signature overexpression
Melanoma
IFNG gene signature overexpression
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
SITC 2023 - 4 weeks (New C3)
Immunotherapy
Sensitive
:
C3
SITC 2023 - 4wk
Immunotherapy
Sensitive: C3 – Early Trials
SITC 2023 - 4 weeks
Immunotherapy
Sensitive
:
C3
SITC 2023 - 4 weeks - (New C3)
CDKN2A deletion + CDKN2B deletion + MTAP deletion + TERT mutation
Melanoma
CDKN2A deletion + CDKN2B deletion + MTAP deletion + TERT mutation
Melanoma
MRTX1719
Sensitive: C4 – Case Studies
Cancer Discov - 4 weeks (New C4)
MRTX1719
Sensitive
:
C4
Cancer Discov - 4wk
MRTX1719
Sensitive: C4 – Case Studies
Cancer Discov - 4 weeks
MRTX1719
Sensitive
:
C4
Cancer Discov - 4 weeks - (New C4)
BRAF V600
Melanoma
BRAF V600
Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
trametinib
Resistant: A1 - Approval
trametinib
Resistant
:
A1
trametinib
Resistant: A1 - Approval
trametinib
Resistant
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
No biomarker
Cutaneous Melanoma
No biomarker
Cutaneous Melanoma
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
LDH elevation
Melanoma
LDH elevation
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
aldesleukin
Sensitive: A1 - Approval
aldesleukin
Sensitive
:
A1
aldesleukin
Sensitive: A1 - Approval
aldesleukin
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
nivolumab/relatlimab
Sensitive: A1 - Approval
nivolumab / relatlimab
Sensitive
:
A1
nivolumab/relatlimab
Sensitive: A1 - Approval
nivolumab / relatlimab
Sensitive
:
A1
BRAF V600 wild-type
Melanoma
BRAF V600 wild-type
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
nivolumab/relatlimab
Sensitive: A1 - Approval
nivolumab / relatlimab
Sensitive
:
A1
nivolumab/relatlimab
Sensitive: A1 - Approval
nivolumab / relatlimab
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login